How malaria detects and shields itself from approaching immune cells
New insight on how malaria cells shield themselves from destruction opens avenues for the development of novel antimalarial drugs
Malaria parasites can sense a molecule produced by approaching immune cells and then use it to protect themselves from destruction, according to new findings published today in eLife.
The study, led by scientists from the Agency for Science, Technology and Research’s (A*STAR) Singapore Immunology Network (SIgN), reveals a previously unknown reversible mechanism that malaria uses to evade the immune system, paving the way towards new antimalarial drugs.
As malaria parasites mature within blood cells, they become more recognisable by the immune system as intruders. But the parasites have evolved ways to evade the immune response, such as by producing sticky molecules on infected red blood cells that allow them to bury themselves in tiny blood vessels.
“One way that malaria-infected red blood cells evade the immune system is to attach directly to non-infected red blood cells to form a flower-shaped structure called a rosette,” explains lead author and SIgN fellow Wenn-Chyau Lee. “The rosette phenomenon has been shown in all human malaria parasites and might be linked to disease severity, but its exact function in the progression of malaria is unclear.”
Recent studies suggest the rosette might work as a mask for the malaria-infected red blood cell and prevent its clearance by the immune system. Lee and the team set out to test this theory.
They started by incubating immune cells called phagocytes with clinical samples of malaria-infected blood cells to study the extent of rosette formation. They found that the rate of rosetting increased by 10-40% in the presence of phagocytes, suggesting that the immune cells trigger the malaria-infected cells to form rosettes.
Next, they attempted to work out how the immune cells were stimulating rosette formation by extracting different components of the blood and analysing which ones were required for rosette formation. Using a step-by-step approach, they identified a substance called human insulin growth factor binding protein 7 (IGFBP7) that was needed for rosettes to form. In fact, when they added IGFBP7 to two different malaria parasite species in the absence of any immune cells, this still stimulated the formation of rosettes.
The team then investigated how the malaria parasites were sensing the IGFBP7 molecule and speculated that it must involve parasite-derived molecules being displayed on the surface of infected red blood cells. Through a process of elimination that involved genetically altering the red blood cells and filtering out components of the blood, they identified a number of molecules that were required for rosette formation. Some of these are thought to be produced by immune cells in response to malaria infection, such as IGFBP7, whereas others are present in the blood with or without the presence of the parasite.
Finally, the scientists investigated whether rosette formation triggered by IGFBP7 could prevent the malaria-infected cells being swallowed up and destroyed by the immune cells – a process called phagocytosis. As anticipated, in the presence of IGFBP7 the rosette formation increased, but the number of infected red blood cells that were engulfed by immune cells was reduced.
“Our work describes a previously unknown defence mechanism in malaria that is mediated by a molecule produced by the very immune cells it is trying to evade,” concludes senior author Laurent Renia, Executive Director of SIgN. “By using this molecule, along with other substances in the blood, malaria-infected blood cells recruit non-infected blood cells to form a rosette shield, allowing them to escape destruction by the immune system. Our results suggest that targeting this mechanism could be an effective approach in the development of novel antimalarial drugs.”
The paper ‘Plasmodium-infected erythrocytes induce secretion of IGFBP7 to form type II rosettes and escape phagocytosis’ can be freely accessed online at https:/
Emily Packer, Senior Press Officer
eLife aims to help scientists accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours in science. We publish important research in all areas of the life and biomedical sciences, including Immunology and Inflammation, and Microbiology and Infectious Disease, which is selected and evaluated by working scientists and made freely available online without delay. eLife also invests in innovation through open-source tool development to accelerate research communication and discovery. Our work is guided by the communities we serve. eLife is supported by the Howard Hughes Medical Institute, the Max Planck Society, the Wellcome Trust and the Knut and Alice Wallenberg Foundation. Learn more at https:/
To read the latest Immunology and Inflammation research published in eLife, visit https:/
And for the latest in Microbiology and Infectious Disease, see https:/
Related Journal Article